Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MIRA
MIRA logo

MIRA Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.974
Open
0.960
VWAP
0.96
Vol
69.67K
Mkt Cap
40.02M
Low
0.950
Amount
66.80K
EV/EBITDA(TTM)
--
Total Shares
42.02M
EV
30.61M
EV/OCF(TTM)
--
P/S(TTM)
--
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.
Show More

Events Timeline

(ET)
2026-06-17
08:30:00
Mira Pharmaceuticals Submits Ketamir-2 Clinical Trial Protocol to FDA
select
2026-06-04 (ET)
2026-06-04
08:30:00
MIRA Pharmaceuticals Signs Exclusive License Agreement with MIRALOGX
select
2026-05-27 (ET)
2026-05-27
08:20:00
MIRA Pharmaceuticals Expands Ketamir-2 License Agreement Worldwide
select
2026-05-14 (ET)
2026-05-14
11:20:00
GH Research Reports Q1 Loss of 26 Cents, Cash at $267.3M
select
2026-05-14
08:20:00
MIRA Pharmaceuticals Reports Positive Results from Ketamir-2 Clinical Trial
select

News

Newsfilter
9.0
06-17Newsfilter
MIRA Submits Phase 2a Trial Protocol for Ketamir-2
  • Clinical Trial Submission: MIRA Pharmaceuticals has submitted a Phase 2a clinical trial protocol to the FDA for Ketamir-2, aimed at evaluating its safety and efficacy in chemotherapy-induced peripheral neuropathy, addressing a significant gap in FDA-approved treatments.
  • Patient Need: Chemotherapy-induced peripheral neuropathy affects 30% to 40% of patients, with approximately 3 million new persistent cases estimated annually worldwide, highlighting the potential market demand and necessity for Ketamir-2 to improve patient quality of life.
  • Trial Design Advantage: The study employs a randomized, double-blind, crossover design where patients will receive either 300 mg or 600 mg of Ketamir-2 or a placebo, allowing for more reliable efficacy signals in a smaller sample size, with each participant's study duration lasting up to 82 days.
  • Safety Record: In the previously completed MIRA-001 Phase 1 study, no serious adverse events were reported among 56 healthy volunteers, supporting the safety profile and once-daily dosing schedule for Ketamir-2, laying a solid foundation for the upcoming Phase 2a trial.
Yahoo Finance
9.0
06-17Yahoo Finance
MIRA Submits Phase 2a Trial Protocol for Ketamir-2
  • Clinical Trial Submission: MIRA Pharmaceuticals has submitted a Phase 2a clinical trial protocol to the FDA for Ketamir-2, aimed at evaluating its safety and efficacy in chemotherapy-induced peripheral neuropathy (CIPN), addressing a significant gap in FDA-approved treatments.
  • Patient Recruitment Criteria: The trial will enroll patients who have experienced persistent CIPN for at least three months, requiring a baseline pain score of 4 or higher, ensuring the study's relevance and potential to provide new treatment options for millions of cancer survivors.
  • Study Design Advantages: Utilizing a randomized, double-blind, crossover design, patients will receive either 300 mg or 600 mg of Ketamir-2 or a placebo, allowing for a more reliable efficacy signal from a smaller sample size, enhancing the scientific rigor of the study.
  • Market Demand Context: CIPN affects 30% to 40% of chemotherapy patients, with no specific treatments available, and MIRA's Ketamir-2 is poised to meet this significant unmet medical need, potentially improving patients' quality of life.
Yahoo Finance
8.5
02-08Yahoo Finance
Cannabis Sector Update: Aurora's Strategic Shift Amid Record Medical Sales
  • Aurora Financial Performance: Aurora Cannabis reported net revenue of $94.2 million for Q3 2026, a 7% year-over-year increase, with global medical cannabis sales reaching $76.2 million, accounting for over 80% of total sales, indicating strong growth potential in the high-margin medical market.
  • Strategic Transformation Plan: Aurora announced plans to gradually exit select Canadian consumer cannabis markets to reduce sales and marketing costs, which is expected to significantly improve overall profit margins in the coming quarters.
  • Canopy Growth Results: Canopy Growth reported net revenue of $90.4 million for Q3 2026, with a nearly 50% reduction in net loss despite weak international performance, reflecting positive progress in cost control and market integration.
  • Cronos Brand Expansion: Cronos Group launched its premium Lord Jones brand in Israel, marking a significant step in its global expansion strategy aimed at meeting local market demands with high-quality products while enhancing brand recognition in international markets.
Benzinga
4.5
2025-07-03Benzinga
US Stocks Likely To Open Higher As Trump Announces Vietnam Trade Deal: S&P 500's Golden Cross 'Reason To Expect Better Than Average Returns,' Says Expert
  • U.S. Stock Market Update: U.S. stock futures rose slightly following President Trump's announcement of a trade deal with Vietnam, while the Nasdaq and NYSE will have early closures for Independence Day. The S&P 500 reached a record high, driven by gains in materials, technology, and energy sectors, despite a decline in private sector jobs reported by ADP.

  • Corporate Highlights: Notable stock movements included a 21% surge for Greenbrier Companies after strong earnings, while Franklin Covey dropped 7.82% due to disappointing results. Xponential Fitness saw an 18.63% increase after an SEC investigation concluded without action, and Global Interactive Technologies skyrocketed 223.31% amid significant corporate changes.

Benzinga
2.0
2025-07-03Benzinga
Why Datadog Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
  • Datadog's S&P 500 Inclusion: Datadog Inc's shares rose 10.6% in pre-market trading after the announcement of its inclusion in the S&P 500 index, effective July 9, 2025, replacing Juniper Networks.

  • Pre-Market Stock Movements: Several stocks experienced significant movements in pre-market trading, with Global Interactive Technologies surging 217.7% and Fly-E Group tumbling 25.8% following a reverse stock split announcement.

Benzinga
9.0
2025-07-03Benzinga
MIRA Pharmaceuticals' Marijuana Analog Mira-55 Shows Potent Pain Relief In Preclinical Study, Stock Jumps 50% After Hours
  • MIRA Pharmaceuticals Stock Surge: MIRA Pharmaceuticals' stock price jumped approximately 50.8% to $1.87 after the announcement of Mira-55, a synthetic marijuana analog that provides pain relief comparable to morphine without psychoactive effects.

  • Regulatory Advancements and Future Prospects: The DEA confirmed that Mira-55 is not a controlled substance, facilitating its clinical development, while the company also progresses with other pain management therapies and an acquisition aimed at enhancing its market position.

Valuation Metrics

The current forward P/E ratio for MIRA Pharmaceuticals Inc (MIRA.O) is 0.00, compared to its 5-year average forward P/E of -3.84. For a more detailed relative valuation and DCF analysis to assess MIRA Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.84
Current PE
0.00
Overvalued PE
-0.24
Undervalued PE
-7.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.99
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.08
Undervalued EV/EBITDA
-2.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Whales Holding MIRA

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is MIRA Pharmaceuticals Inc (MIRA) stock price today?

The current price of MIRA is 0.9524 USD — it has decreased -2.66

What is MIRA Pharmaceuticals Inc (MIRA)'s business?

MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.

What is the price predicton of MIRA Stock?

Wall Street analysts forecast MIRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIRA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is MIRA Pharmaceuticals Inc (MIRA)'s revenue for the last quarter?

MIRA Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is MIRA Pharmaceuticals Inc (MIRA)'s earnings per share (EPS) for the last quarter?

MIRA Pharmaceuticals Inc. EPS for the last quarter amounts to -0.03 USD, decreased -72.73

How many employees does MIRA Pharmaceuticals Inc (MIRA). have?

MIRA Pharmaceuticals Inc (MIRA) has 3 emplpoyees as of June 21 2026.

What is MIRA Pharmaceuticals Inc (MIRA) market cap?

Today MIRA has the market capitalization of 40.02M USD.